NEW HAVEN, Conn., Oct. 23, 2023 /PRNewswire/ -- XINGIMAGING, LLC, and MITRO Biotech Co., Ltd., two recognized lead companies offering quality and excellence in drug development and imaging solutions, have merged to create one company dedicated to providing a full spectrum of CRO & CDMO research service offerings..

康涅狄格州纽黑文市，2023年10月23日/PRNewswire/-XINGIMAGING，LLC和MITRO Biotech Co.，Ltd。这两家公认的领先公司在药物开发和成像解决方案方面提供质量和卓越，已合并创建一家公司致力于提供全方位的CRO＆CDMO研究服务产品。。

As a combined company, Mitro will expand its capabilities to provide full CRO services, including clinical and clinical imaging management, in China and globally. From early development of tracers evaluating disease progression to clinical research and imaging trial management, Mitro will collaborate with pharmaceutical industry leaders to advance the investigation of promising clinical therapeutics and companion diagnostic for precision medicine..

作为一家联合公司，Mitro将扩大其在中国和全球提供全面CRO服务的能力，包括临床和临床影像管理。从评估疾病进展的示踪剂的早期开发到临床研究和影像学试验管理，Mitro将与制药行业领导者合作，推进对有前景的临床治疗和精准医学伴随诊断的研究。。

'We are very excited to welcome XingImaging to the Mitro team. XingImaging's experience and know-how are extraordinarily complementary to Mitro. Expansion of our combined offerings provides our pharmaceutical industry and biotech partners with a continuum of research services utilizing start-of-the-art technology of molecular imaging and radio-pharmaceutical in-vivo targeting,' said Grant Luo, Chairman of Mitro.

“我们非常高兴欢迎XingImaging加入Mitro团队。XingImaging的经验和专业知识与Mitro非常互补。Mitro主席罗格兰特说，我们联合产品的扩张为我们的制药行业和生物技术合作伙伴提供了利用分子成像和放射性药物体内靶向的最先进技术开始的连续研究服务。

Furthermore, 'XingImaging's clinical imaging network in China, and its extensive experience in facilitating rapid access to the most advanced neuroimaging tracer compounds, will enhance Mitro's objectives for future success.'.

此外，“XingImaging在中国的临床成像网络，以及在促进快速获取最先进的神经影像示踪化合物方面的丰富经验，将提高Mitro未来成功的目标。”。

Founded in 2012, MITRO Biotech Co., Ltd. was the first company in China to provide pre-clinical and clinical contract research services by applying molecular imaging technologies.

MITRO Biotech Co.，Ltd。成立于2012年，是中国第一家应用分子成像技术提供临床前和临床合同研究服务的公司。

'Our team has grown side-by-side for more than 10 years,' said Luo. 'Our culture is enriched by the combined expertise and skills that each member brings to the table. As a united force, together we will address the rapidly increasing demands for using PET imaging in clinical research trials in China.

“我们的团队已经并排成长了十多年，”罗说我们的文化丰富了每个成员带到餐桌上的综合专业知识和技能。作为一个统一力量，我们将共同解决在中国临床研究试验中使用PET成像的快速增长的需求。

Mitro will accelerate new radiotracer development through non-clinical investigations and Phase 1-3 clinical imaging research to evaluate disease progression, novel therapeutics, and radio-isotope targeted therapy. Mitro will provide one-stop-shop service from non-clinical CRO, clinical CRO, imaging CRO to drug registration, as well as CDMO service to achieve market authorization approval.'.

Mitro将通过非临床研究和1-3期临床影像学研究加速新的放射性示踪剂开发，以评估疾病进展，新疗法和放射性同位素靶向治疗。Mitro将提供非临床CRO，临床CRO，影像CRO到药物注册的一站式服务，以及CDMO服务，以实现市场授权批准。

Dr. Gilles Tamagnan, Ph.D., XingImaging Co-Founder and CEO will serve as Mitro's CEO.  The individual contribution of company leaders and advisors delivers an average of more than 30 years of expertise. Drs. Piu Chan and Kenneth Marek, pioneers in neurological medicine and imaging science, will remain as senior advisors..

Gilles Tamagnan博士，XingImaging联合创始人兼首席执行官将担任Mitro的首席执行官。公司领导者和顾问的个人贡献平均提供超过30年的专业知识。神经医学和影像科学先驱Piu Chan博士和Kenneth Marek博士将继续担任高级顾问。。

Dr. Gilles Tamagnan, reflecting on this acquisition, said, 'This is an amazing opportunity to integrate two thoroughly experienced, dedicated, and driven organizations into one. As a merged company, Mitro will provide end-to-end solutions from bench to bedside for developing emerging new PET tracers, evaluating therapeutics, and managing clinical trials, to attain reliable results.

Gilles Tamagnan博士反思这一收购，他说：“这是一个惊人的机会，将两个经验丰富，专注和驱动的组织整合到一个组织中。作为一家合并公司，Mitro将提供从实验室到床边的端到端解决方案，用于开发新兴的PET示踪剂，评估治疗方法和管理临床试验，以获得可靠的结果。

This equates to a highly qualified team, one that I am truly honored to lead to success.'.

这相当于一支高素质的团队，我真的很荣幸能够取得成功。”。

Chestnut Partners, Inc. acted as exclusive financial advisor to XingImaging in this transaction, and Goodwin Procter LLP served as legal counselor for XingImaging.  DLA Piper UK LLC served as legal counselor for Mitro, and PricewaterhouseCoopers served as consultant in financial due diligence and closing review..

Chestnut Partners，Inc。在此交易中担任XingImaging的独家财务顾问，Goodwin Procter LLP担任XingImaging的法律顾问。DLA Piper UK LLC担任Mitro的法律顾问，PricewaterhouseCoopers担任财务尽职调查和结案审查顾问。。

About XingImaging LLCXingImaging is a widely recognized US-based biomarker imaging company leading radiopharmaceutical imaging trials in China. With firmly rooted study teams on the ground in China and the US, XingImaging works in collaboration with biotech and pharmaceutical companies for the testing and advancement of therapeutics through brain imaging.

关于XingImaging LLCXingImaging是一家广泛认可的美国生物标志物成像公司，在中国领导着放射性药物成像试验。XingImaging拥有扎根的中国和美国研究团队，与生物技术和制药公司合作，通过脑成像测试和推进治疗方法。

XingImaging's world-renowned scientific expertise gives it an advantage, opening the way for academic and industry sponsors to conduct cutting-edge research in China. With each of the co-founders and company leaders having an average of 25-plus years of experience, this knowledge is one of XingImaging's greatest attributes..

XingImaging拥有世界知名的科学专长，为学术界和行业赞助商在中国开展尖端研究开辟了道路。每个共同创始人和公司领导者平均拥有25年以上的经验，这种知识是XingImaging最大的属性之一。。

About MITRO Biotech Co, Ltd.MITRO Biotech Co., Ltd. is a molecular imaging contract research organization (MI-CRO) company in China. MITRO provides outstanding contract research for new drug development using radiolabeling and molecular imaging techniques. MITRO provides integrated solutions, including evaluation of potential therapeutics, biodistribution, pharmacokinetics and pharmacodynamics.

关于MITRO Biotech Co，Ltd.MITRO Biotech Co.，Ltd。是中国的分子影像合同研究组织（MI-CRO）公司。MITRO使用放射性标记和分子成像技术为新药开发提供出色的合同研究。MITRO提供综合解决方案，包括评估潜在的治疗方法，生物分布，药代动力学和药效学。

MITRO provides translational research using a wide range of non-clinical through Phase 0 clinical trial services. MITRO focuses on cancer, coronary heart disease, Alzheimer's disease, epilepsy, Parkinson disease, rheumatoid arthritis, diabetes, gene expression, stem cell research, etc..

MITRO通过0期临床试验服务提供广泛的非临床转化研究。MITRO专注于癌症，冠心病，阿尔茨海默病，癫痫，帕金森病，类风湿性关节炎，糖尿病，基因表达，干细胞研究等。。

Contacts:MITRO Biotech, Co, LtdHaowei Wu [email protected]http://www.mi-tro.com/

联系人：MITRO生物技术有限公司吴浩伟〔emailprotected〕http://www.mi-tro.com/

XingImaging, LLCRebecca Evans[email protected]https://Xingimaging.com/

XingImaging，LLCRebecca Evans〔email protected〕https://Xingimaging.com/

SOURCE XingImaging, LLC

资料来源XingImaging，LLC